{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:51:14Z","timestamp":1792799474764,"version":"4.5.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nanomedicine can improve cancer immunotherapy by enabling tumor-selective delivery and active modulation of the tumor immune microenvironment (TIME), yet the global structure and translational trajectory of this interdisciplinary field remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Web of Science Core Collection and Scopus were searched from inception to February 1, 2025. After deduplication and screening, 1,110 English-language articles and reviews were included. VOSviewer, CiteSpace, Bibliometrix, and Python were used to analyze publication trends, collaboration networks, journal relationships, co-citation structures, citation bursts, and keyword evolution. Non-negative matrix factorization was applied to citation-burst references to identify latent thematic structures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Publication output increased sharply after 2022, and studies published during 2022\u20132025 accounted for 79.9% of the dataset. China led in publication volume and institutional productivity, whereas the United States showed strong citation influence. Soochow University, the Chinese Academy of Sciences, and Sichuan University were the most productive institutions. Three major themes emerged: photodynamic therapy combined with immune checkpoint blockade; tumor-microenvironment remodeling and melanoma immunotherapy; and nanomaterial-mediated immune activation involving cell death, antigen release, and adaptive antitumor responses. Temporal mapping demonstrated a shift from passive nanoparticle delivery toward active immune-regulatory nanoplatforms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>By integrating dual-database bibliometrics, citation-burst analysis, temporal knowledge mapping, and topic modeling, this study clarifies the intellectual structure and evolution of nano-immuno-oncology. Future research should prioritize biologically predictive models, reproducible manufacturing, standardized characterization, long-term safety assessment, biomarker-guided patient selection, and clinically scalable designs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1895225","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:25:14Z","timestamp":1788495914000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Nanomedicine and the tumor immune microenvironment in cancer immunotherapy: a bibliometric and knowledge-mapping analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Yanzhen","family":"Mai","sequence":"first","affiliation":[{"name":"Huizhou Health Sciences Polytechnic","place":["Huizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqin","family":"Wang","sequence":"additional","affiliation":[{"name":"Huizhou Health Sciences Polytechnic","place":["Huizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Li","sequence":"additional","affiliation":[{"name":"Huizhou Health Sciences Polytechnic","place":["Huizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Lu","sequence":"additional","affiliation":[{"name":"Huizhou Health Sciences Polytechnic","place":["Huizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Luo","sequence":"additional","affiliation":[{"name":"Huizhou Health Sciences Polytechnic","place":["Huizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinli","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Huizhou Health Sciences Polytechnic","place":["Huizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoran","family":"Duan","sequence":"additional","affiliation":[{"name":"National Engineering Laboratory for Internet Medical Systems and Applications, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Guo","sequence":"additional","affiliation":[{"name":"National Engineering Laboratory for Internet Medical Systems and Applications, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, Henan, China"]},{"name":"Department of Rehabilitation Medicine, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: Indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"25","author":"Roerden","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70321","article-title":"Immune surveillance and immune escape in cancer: Mechanisms and immunotherapy","volume":"6","author":"Peng","year":"2025","journal-title":"MedComm (2020)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00986-3","article-title":"The tumor microenvironment's role in the response to immune checkpoint blockade","volume":"6","author":"Aliazis","year":"2025","journal-title":"Nat Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.11.009","article-title":"Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy","volume":"470","author":"Lei","year":"2020","journal-title":"Cancer Lett"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70754","article-title":"Intratumoral microorganisms in tumors: Current understanding and emerging therapeutic strategies","volume":"7","author":"Zhang","year":"2026","journal-title":"MedComm (2020)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12943-025-02477-6","article-title":"Turning cold tumors into hot tumors to ignite immunotherapy","volume":"24","author":"Liu","year":"2025","journal-title":"Mol Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12943-023-01885-w","article-title":"Exploiting innate immunity for cancer immunotherapy","volume":"22","author":"Yi","year":"2023","journal-title":"Mol Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.05.010","article-title":"Integrative approaches to cancer immunotherapy","volume":"5","author":"Szeto","year":"2019","journal-title":"Trends Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.011","article-title":"Understanding and treating the inflammatory adverse events of cancer immunotherapy","volume":"184","author":"Dougan","year":"2021","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13045-019-0817-3","article-title":"Delivery strategies of cancer immunotherapy: recent advances and future perspectives","volume":"12","author":"Zhao","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202312169","article-title":"Nanomedicine tumor targeting","volume":"36","author":"Lammers","year":"2024","journal-title":"Adv Mater"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7150\/thno.87854","article-title":"Stimuli-activatable nanomedicine meets cancer theranostics","volume":"13","author":"Li","year":"2023","journal-title":"Theranostics"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.0c00518","article-title":"Tumor-targeted nanomedicine for immunotherapy","volume":"53","author":"Cabral","year":"2020","journal-title":"Acc Chem Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-021-01096-0","article-title":"Nanomaterials for cancer therapy: current progress and perspectives","volume":"14","author":"Cheng","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12943-025-02270-5","article-title":"Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines","volume":"24","author":"Maksymova","year":"2025","journal-title":"Mol Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.4c09190","article-title":"Tumor microenvironment-derived exosomes: A double-edged sword for advanced T cell-based immunotherapy","volume":"18","author":"Lu","year":"2024","journal-title":"ACS Nano"},{"key":"B22","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat Rev Mater"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-024-01754-7","article-title":"A translational framework to DELIVER nanomedicines to the clinic","volume":"19","author":"Joyce","year":"2024","journal-title":"Nat Nanotechnol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202513567","article-title":"Tumor microenvironment-responsive nanomedicines for potentiating cancer immunotherapy","volume":"12","author":"Huang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/asi.20317","article-title":"CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature","volume":"57","author":"Chen","year":"2006","journal-title":"J Am Soc Inf Sci Technol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2025.07.038","article-title":"Nano-assisted dynamically assembled hydrogels with strong tissue adhesion and proactive immunomodulation for bone defect repair","volume":"53","author":"Chen","year":"2025","journal-title":"Bioact Mater"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2026.103162","article-title":"Tumor microenvironment responsive nano-immunoregulator for precision cancer photodynamic immunotherapy","volume":"38","author":"Chang","year":"2026","journal-title":"Mater Today Bio"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5c20535","article-title":"Dual-targeting mRNA cancer vaccines for simultaneous antigen presentation in dendritic and tumor cells","volume":"20","author":"Kim","year":"2026","journal-title":"ACS Nano"},{"key":"B29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J Nanobiotechnol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2026.189592","article-title":"Emerging advantages of nano delivery systems in enhancing CAR-T\/CRISPR-Cas9 mediated cancer therapeutics","volume":"1881","author":"Sahu","year":"2026","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114445","article-title":"Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment","volume":"188","author":"Gao","year":"2022","journal-title":"Adv Drug Delivery Rev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S293427","article-title":"Advances in multiple stimuli-responsive drug-delivery systems for cancer therapy","volume":"16","author":"Jia","year":"2021","journal-title":"Int J Nanomedicine"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104866","article-title":"Nano-omics and nanomedicine target microbial carcinogenesis: Tumor microenvironment reprograming to clinical translation","volume":"213","author":"Kawuribi","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5c15117","article-title":"Next-generation nanomotors: a biomedical platform for precision tumor targeting and treatment","volume":"20","author":"Zhang","year":"2026","journal-title":"ACS Nano"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5c17200","article-title":"An intracellular gelated macrophage-based vaccine for tumor immunotherapy","volume":"20","author":"An","year":"2026","journal-title":"ACS Nano"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5c14753","article-title":"Reprogramming immunosuppressive niches and the cancer immunity cycle in pancreatic cancer with neoantigen mRNA plus immune adjuvant nanocarrier strategies","volume":"19","author":"Nel","year":"2025","journal-title":"ACS Nano"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202513548","article-title":"Selective membrane protein enrichment enables defined biomimetic nanoparticles for endothelial targeting","volume":"22","author":"Raviv","year":"2026","journal-title":"Small"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5c14644","article-title":"Remodeling the tumor microenvironment: An emerging paradigm for reinvigorating immunologically cold tumors and advancing cancer immunotherapy","volume":"20","author":"Zeng","year":"2026","journal-title":"ACS Nano"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5c00223","article-title":"Immune-modulating dual-targeted nanomaterials for low-temperature photothermal-photodynamic-chemodynamic therapy of osteosarcoma targeting tumor and endothelial cells","volume":"19","author":"Pan","year":"2025","journal-title":"ACS Nano"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5c06202","article-title":"Cancer cell membrane-coated homodimer prodrug nanoassemblies to simultaneously deliver prodrugs and immune adjuvants for combined chemo-immunotherapy","volume":"19","author":"Zhao","year":"2025","journal-title":"ACS Nano"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2025.114759","article-title":"Macrophage-membrane-engineered NIR II biomimetic nanomaterials for enhanced synergistic chemo-photothermal immunotherapy in cancer treatment","volume":"253","author":"Yao","year":"2025","journal-title":"Colloids Surf B Biointerfaces"},{"key":"B42","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1186\/s12951-025-03740-0","article-title":"Harnessing smart nanomaterials to reprogram neutrophil plasticity in immune modulation","volume":"23","author":"Luo","year":"2025","journal-title":"J Nanobiotechnol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.0c00475","article-title":"Nano-immune-engineering approaches to advance cancer immunotherapy: Lessons from ultra-pH-sensitive nanoparticles","volume":"53","author":"Li","year":"2020","journal-title":"Acc Chem Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ymthe.2024.01.005","article-title":"The landscape of nanoparticle-based siRNA delivery and therapeutic development","volume":"32","author":"Moazzam","year":"2024","journal-title":"Mol Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.9b00368","article-title":"Lipid nanoparticle technology for clinical translation of siRNA therapeutics","volume":"52","author":"Kulkarni","year":"2019","journal-title":"Acc Chem Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114990","article-title":"Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications","volume":"200","author":"Jeong","year":"2023","journal-title":"Adv Drug Delivery Rev"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s44222-023-00138-1","article-title":"Controlling the biodistribution and clearance\u00a0of nanomedicines","volume":"2","author":"Cabral","year":"2024","journal-title":"Nat Rev Bioeng"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s44222-024-00154-9","article-title":"The mechanisms of nanoparticle delivery to solid tumours","volume":"2","author":"Nguyen","year":"2024","journal-title":"Nat Rev Bioeng"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2023.103045","article-title":"Progress and challenges in the translation of cancer nanomedicines","volume":"85","author":"Tong","year":"2024","journal-title":"Curr Opin Biotechnol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1895225\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:25:15Z","timestamp":1788495915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1895225\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":49,"alternative-id":["10.3389\/fonc.2026.1895225"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1895225","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1895225"}}